Opaleye Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-654,943
| Closed | -$1.41M | – | 49 |
|
|
2024
Q3 | $1.41M | Sell |
654,943
-210,500
| -24% | -$453K | 0.23% | 40 |
|
|
2024
Q2 | $4.47M | Buy |
865,443
+77,898
| +10% | +$402K | 1.02% | 29 |
|
|
2024
Q1 | $4.21M | Buy |
787,545
+428,175
| +119% | +$2.29M | 0.92% | 29 |
|
|
2023
Q4 | $2.8M | Buy |
+359,370
| New | +$2.8M | 0.74% | 34 |
|
|
2018
Q2 | – | Sell |
-7,407
| Closed | -$961K | – | 42 |
|
|
2018
Q1 | $961K | Hold |
7,407
| – | – | 0.27% | 35 |
|
|
2017
Q4 | $720K | Sell |
7,407
-4,250
| -36% | -$413K | 0.23% | 33 |
|
|
2017
Q3 | $1.72M | Buy |
11,657
+707
| +6% | +$104K | 0.61% | 30 |
|
|
2017
Q2 | $1.76M | Buy |
10,950
+8,435
| +335% | +$1.36M | 0.74% | 31 |
|
|
2017
Q1 | $400K | Buy |
+2,515
| New | +$400K | 0.2% | 42 |
|